BNP Paribas Asset Management
ARNA

BNP Paribas Asset Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History

BNP Paribas Asset Management’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-350,856
Closed -$32.6M – 964
2021
Q4 		$32.6M Sell
350,856
-83,152
-19% -$5.48M 0.11% 228
2021
Q3 		$25.8M Buy
434,008
+19,586
+5% +$1.16M 0.1% 244
2021
Q2 		$28.3M Buy
414,422
+162,058
+64% +$10.6M 0.1% 249
2021
Q1 		$17.5M Sell
252,364
-50,452
-17% -$3.88M 0.07% 318
2020
Q4 		$23.3M Buy
302,816
+33,247
+12% +$2.49M 0.11% 226
2020
Q3 		$20.2M Buy
269,569
+7,261
+3% +$484K 0.11% 216
2020
Q2 		$16.5M Buy
+262,308
New +$14.4M 0.11% 220
2015
Q2 		– Sell
-6,745
Closed -$295K – 1087
2015
Q1 		$295K Buy
+6,745
New +$313K ﹤0.01% 988

BNP Paribas Asset Management's ARNA Position: Q1 2022 in Review

BNP Paribas Asset Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 350,856 shares — an estimated $32.6M sold.

BNP Paribas Asset Management first reported a position in ARNA in Q1 2015 and held it in 8 quarters. The position peaked at $32.6M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

  • BNP Paribas Asset Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
  • BNP Paribas Asset Management sold 350,856 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $32.6M.
  • BNP Paribas Asset Management first reported a position in Arena Pharmaceuticals Inc in Q1 2015 and held it in 8 quarters.
  • BNP Paribas Asset Management's Arena Pharmaceuticals Inc position peaked at $32.6M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on BNP Paribas Asset Management's 13F filing for Q1 2022, filed 12 May 2022.